Study Overview
This study focuses on treating IgA nephropathy, a kidney condition, using two medications: Enteric-coated Mycophenolate Sodium (EC-MPS) and hydroxychloroquine. The goal is to see if combining these two treatments is more effective than using hydroxychloroquine alone.
What We Are Doing
We are conducting a trial with 96 patients from 12 hospitals in Shanxi Province, China. Patients will be randomly divided into two groups: one group will receive EC-MPS along with hydroxychloroquine, while the other group will receive hydroxychloroquine only. Both groups will also get standard care to manage their blood pressure.
Measuring Success
The main measure of success will be the change in protein levels in urine after 6 months. We will follow up with patients for a total of 12 months to monitor their progress.
Ethical Considerations
This study has been approved by the Ethics Committee of Shanxi Medical University Second Hospital. Participants will provide informed consent before joining the trial.
Opportunities for Clinics and Patients
Based on the trial data, clinics can set clear goals for treatment outcomes, focusing on reducing proteinuria in patients with IgA nephropathy. This can lead to better management strategies and improved patient care.
Using AI in Healthcare
We recommend selecting AI tools that meet specific clinical needs. These tools can help track patient outcomes and improve treatment plans based on real-world data from the trial.
Next Steps
Start with a pilot project to implement these findings, using AI solutions to monitor results and expand on successful strategies in treating IgA nephropathy.
Contact Us
For more information on AI solutions in medical management, reach out to us:
